Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALGeneric

LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE

LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE

Standard Dose
150MG;200MG;300MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE is listed in Drugs@FDA under application 205626 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE Form and strength TABLET;ORAL - 150MG;200MG;300MG Sponsor MICRO LABS Submission history Latest submission status date: 2018-08-13 00:00:00.

Structured Monograph

Clinical summary

Approval overview LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE is listed in Drugs@FDA under application 205626 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE Form and strength TABLET;ORAL - 150MG;200MG;300MG Sponsor MICRO LABS Submission history Latest submission status date: 2018-08-13 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.